



(11) **EP 3 093 345 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(51) Int Cl.:
C07K 14/005 ^(2006.01) **C12N 7/00** ^(2006.01)

(48) Corrigendum issued on:
24.07.2019 Bulletin 2019/30

(45) Date of publication and mention
of the grant of the patent:
24.04.2019 Bulletin 2019/17

(21) Application number: **16176100.2**

(22) Date of filing: **25.07.2008**

(54) **BACULOVIRAL VECTORS COMPRISING REPEATED CODING SEQUENCES WITH DIFFERENTIAL CODON BIASES**

BACULOVIRUS-VEKTOREN MIT WIEDERHOLTEN CODIERUNGSSEQUENZEN MIT DIFFERENTIELLEN CODON-VORSPANNUNGEN

VECTEURS BACULOVIRAUX COMPORTANT DES SÉQUENCES DE CODAGE RÉPÉTÉES AVEC DES POLARISATIONS DE CODONS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: **26.07.2007 US 952081 P**
26.07.2007 EP 07113257

(43) Date of publication of application:
16.11.2016 Bulletin 2016/46

(60) Divisional application:
19170381.8

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
08779058.0 / 2 173 888

(73) Proprietor: **UniQure IP B.V.**
1105 BP Amsterdam (NL)

(72) Inventors:
• **Bakker, Andrew Christian**
1105 BP Amsterdam (NL)
• **Hermens, Wilhelmus Theodorus Johannes Maria Christiaan**
1105 BP Amsterdam (NL)

(74) Representative: **Nederlandsch Octrooibureau**
P.O. Box 29720
2502 LS The Hague (NL)

(56) References cited:
US-A1- 2003 228 696

• **URABE M ET AL: "Insect cells as a factory to produce adeno-associated virus type 2 vectors", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 13, no. 16, 1 November 2002 (2002-11-01), pages 1935-1943, XP002394454, ISSN: 1043-0342**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 093 345 B8

- KOHLBRENNER ET AL: "Successful Production of Pseudotyped rAAV Vectors Using a Modified Baculovirus Expression System", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 12, no. 6, December 2005 (2005-12), pages 1217-1225, XP005176630, ISSN: 1525-0016